Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,771 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vira Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000745
View directory record Official record
Conditions
HIV Infections
Interventions
Hepatitis B Vaccine (Recombinant), gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1991
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

NCT02421367
View directory record Official record
Conditions
Dengue
Interventions
TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
20 Years to 49 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 4, 2026, 10:25 PM EDT
Completed No phase listed Observational Results available

Genetic and Biochemical Markers of Interferon-Induced Depression.

NCT00252538
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Long Beach, California • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

NCT02840487
View directory record Official record
Conditions
Prevention of Zika Infection, Zika-Specific Immune Response
Interventions
VRC-ZKADNA085-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 4, 2026, 10:25 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

NCT05616793
View directory record Official record
Conditions
LCA5
Interventions
AAV8.hLCA5
Biological
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
4 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Assess the Safety of a New Influenza Vaccine

NCT01104493
View directory record Official record
Conditions
Healthy
Interventions
Monovalent Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 4, 2026, 10:25 PM EDT
Recruiting Phase 2 Interventional

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Doravirine, 2 NRTIs, DOR/3TC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
4 Weeks to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

NCT04019444
View directory record Official record
Conditions
Rabies, Rabies Immunisation
Interventions
ChAd155-RG, Placebo, Rabies Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer

NCT02703493
View directory record Official record
Conditions
Cancer of the Oropharynx
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 4, 2026, 10:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

NCT04398433
View directory record Official record
Conditions
Respiratory Papillomatosis
Interventions
INO-3107, CELLECTRA® 2000
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 4, 2026, 10:25 PM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

NCT03397706
View directory record Official record
Conditions
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Interventions
VRx-3996 and valganciclovir
Combination Product
Lead sponsor
Viracta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

NCT00000684
View directory record Official record
Conditions
HIV Infections
Interventions
Dextran sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

NCT04540406
View directory record Official record
Conditions
Suspected or Confirmed COVID-19
Interventions
NBT-NM108, Usual Care Only
Drug · Other
Lead sponsor
Notitia Biotechnologies Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 4, 2026, 10:25 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

NCT07003984
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP vaccine, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
1 Year to 11 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
8
States / cities
Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

NCT02433652
View directory record Official record
Conditions
Dengue
Interventions
Recombinant live attenuated trivalent dengue vaccine, Placebo, rDEN2Δ30-7169 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 4, 2026, 10:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07147517
View directory record Official record
Conditions
Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions
Component A0, Component A1, Component A2, Component B
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
La Jolla, California • San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

NCT01329978
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
44
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 4, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes

NCT00722423
View directory record Official record
Conditions
Hepatitis C
Interventions
Integrated care model, Usual Care Model
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Palo Alto, California • San Diego, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 4, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional Results available

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

NCT06585150
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Cullman, Alabama • Guntersville, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 4, 2026, 10:25 PM EDT